stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.63
0.21
+2.23%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Operating cash flow
Telix Pharmaceuticals Limited's operating cash flow for fiscal 2025 was −$17.3M, compared with $27.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $51.9M. Telix Pharmaceuticals Limited ranks 35th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$17.3M | — |
| FY2024 | $27.5M | 73.24% |
| FY2023 | $15.9M | — |
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited | $51.9M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. compare | −$66.9M |
| CELC Celcuity, Inc. compare | −$191.7M |
| VRDN Viridian Therapeutics, Inc. compare | −$341.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$347.4M |
| DNLI Denali Therapeutics Inc. compare | −$444.2M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item